| Similar Articles |
|---|
 |
ifeminists
April 29, 2004
Tony Zizza |
Stop Selling Depression and Drugs To Men Author questions how it can be wrong to profile terrorists, but okay to profile a particular gender as a profitable market for medications and subjective mental health labels?   |
ifeminists
September 28, 2005
Tony Zizza |
Paxil Protest Long Overdue Paxil is an extremely powerful and dangerous antidepressant that has created havoc for millions of people and their families worldwide. The SSRI Citizen-sponsored Paxil Protest in Philadelphia is long overdue. |
The Motley Fool
March 7, 2005
Brian Gorman |
Glaxo in Hot Water Glaxo's problems with the FDA could have been avoided. Investors can only hope that the FDA is in a forgiving mood. |
ifeminists
November 24, 2004
Tony Zizza |
The Problem With Ron Artest and Antidepressants It is very sad to see both the sports world and the world of "mental health" drowning in a sea of subjective psychiatric disorders and lethal drugs. Whatever happened to self-restraint? Self-reliance? Knowing what is right behavior and what is wrong behavior? |
The Motley Fool
July 28, 2005
Stephen D. Simpson |
Glaxo Keeps It Going Despite missing sales from the depression franchise, Glaxo managed to post respectable quarterly results. |
The Motley Fool
April 28, 2005
Stephen D. Simpson |
Glaxo Works to Stay on Track With FDA issues near resolution, Glaxo should continue its respectable growth trajectory. Investors looking at the pharmaceutical space would do well to at least consider this stock. |
The Motley Fool
January 19, 2011
Cliff D'Arcy |
Glaxo Stung by Legal Bill GSK shareholders are hit by costly legal settlements. |
The Motley Fool
June 3, 2004
Brian Gorman |
Spitzer Chases Glaxo Did the drug company GlaxoSmithKline withhold information about the effects of Paxil in children? No doubt the bad publicity will continue to hit the stock. |
The Motley Fool
October 28, 2004
Bill Mann |
Glaxo's Mild Depression The British drug maker sees increased generic competition for its anti-depressant drugs. Total constant currency sales slipped to $7.7 billion in the current quarter from $8.5 billion last year. |
BusinessWeek
October 4, 2004
Kerry Capell |
Why Glaxo Can't Shake the Flu Sales are weakening as hot sellers come off-patent. But the pipeline looks healthy. And there's the rub. Just when GSK's image is at a new low, its prospects are improving. |
Chemistry World
July 2, 2012
Andrew Turley |
$3bn GSK fine sets new industry record The GlaxoSmithKline fine, which relates to antidepressant brands Paxil (paroxetine) and Wellbutrin (bupropion) and diabetes brand Avandia (rosiglitazone), is the largest payment ever made by a drug company. |
The Motley Fool
April 5, 2011
Frank Vinluan |
GSK in Emerging Markets: Why Sales Staff There Are Key to Global Strategy GlaxoSmithKline's rivalry with top drug companies such as Pfizer goes beyond the products they sell. In some emerging markets, it now also extends to the staff they're fighting to keep. |
Pharmaceutical Executive
August 1, 2012
Julian Upton |
Brand Building -- Not! As a drug company promoting a drug free Olympiad, GSK wins our gold hands down for finally putting the industry's best face forward on the last frontier of advertising and the TV sets of Europe. |
The Motley Fool
September 15, 2011
Frank Vinluan |
GSK's New Drug Marketing Model: Pharma Reps As Educators, Not Sellers The conversation between sales reps and doctors today is vastly different compared to one year ago. |
The Motley Fool
October 25, 2007
Brian Lawler |
Rope-a-Dope at GSK? Following the negative FDA panel hearings and safety review of diabetes drug Avandia and exchange rate movements against it, revenue fell 3% in the third quarter for GlaxoSmithKline. Operating income and profit were also slightly down. |
Chemistry World
January 30, 2007
Bea Perks |
BBC and GSK Battle Over Seroxat The UK pharmaceutical giant, which has spent the past few years fighting off accusations of risks associated with its market-leading anti-depressant, has rejected fresh claims that it improperly withheld medical trial information in the 1990s. |
The Motley Fool
June 3, 2011
Frank Vinluan |
GSK Sees Positive Results on Asthma, COPD Drug Expected to Succeed Advair GSK gets good news. |
The Motley Fool
June 14, 2007
Brian Lawler |
Dueling Fools: GlaxoSmithKline Bull Rebuttal Investors who think this pharma's market cap is too large would be missing out on the chance to own one of the best-run companies in the most exciting industry. |
